Eric Dobmeier, Chinook Therapeutics CEO
April 11, 2023 10:46 AM EDTUpdated April 13, 08:48 AM
R&D

Chi­nook paus­es PhI kid­ney dis­ease tri­al af­ter se­ri­ous ad­verse event

Paul Schloesser

Associate Editor

Chi­nook Ther­a­peu­tics said it tem­porar­i­ly halt­ed dos­ing par­tic­i­pants in the Phase I tri­al of its treat­ment for an ul­tra-rare ge­net­ic kid­ney dis­ease af­ter one of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times